Patents Assigned to CULLGEN (SHANGHAI), INC.
  • Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
    Patent number: 12065442
    Abstract: Bivalent compounds, compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof are provided. Methods for identifying such bivalent compounds are provided, either.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: August 20, 2024
    Assignee: CULLGEN (SHANGHAI), INC.
    Inventors: Jing Liu, Liqun Chen
  • Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
    Patent number: 11969472
    Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: April 30, 2024
    Assignee: CULLGEN (SHANGHAI), INC.
    Inventors: Jialiang Wang, Xiaoran Han, Jing Liu, Liqun Chen